Hanson Wade have taken the decision to cancel this meeting.
Please do accept our apologies for any inconvenience or disappointment this will cause.
Please register your interest here if you would like updates on the meeting or topic.
Exclusive Bonus Content!
We are proud to offer you a number of exclusive pre-recorded presentations which will be available to watch during the virtual event as well as post-event. Our bonus content speaker will be attending the event and welcome you to ask questions using our 1-1 chat function.
Selective PI3K Inhibitors – Rhizen’s Journey Overcoming the Pitfalls
- Selective PI3K inhibitors – Game changing therapies to treat haematological malignancies
- First generation therapeutic agents – safety vs efficacy
- Umbralsib and Tenalisib – Second generation PI3K delta and delta/gamma inhibitors – therapeutic potential